Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
Top Cited Papers
- 22 April 2012
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (1), 101-109
- https://doi.org/10.1002/pbc.24188
Abstract
Background Hemophagocytic lymphohistiocytosis (HLH) is a life‐threatening hyperinflammatory syndrome that remains difficult to treat. Even with current standard HLH therapy, only approximately half of patients will experience complete resolution of disease, and early mortality remains a significant problem. Salvage therapies have been described only in limited case reports, and there are no large studies of second‐line therapies. Procedure We reviewed the charts of 22 pediatric and adult patients who received alemtuzumab for the treatment of refractory HLH at our center or in consultation with our group. Results Patients had received conventional therapies for a median of 8 weeks (range: 2–70) prior to alemtuzumab, and treatment immediately prior to alemtuzumab included dexamethasone (100%), etoposide (77%), cyclosporine (36%), intrathecal hydrocortisone ± methotrexate (23%), methylprednisolone (9%), and rituximab (14%). Patients received a median dose of 1 mg/kg alemtuzumab (range: 0.1–8.9 mg/kg) divided over a median of 4 days (range: 2–10). Fourteen patients experienced an overall partial response, defined as at least a 25% improvement in two or more quantifiable symptoms or laboratory markers of HLH 2 weeks following alemtuzumab (64%). Five additional patients had a 25% or greater improvement in a single quantifiable symptom or laboratory marker of HLH (23%). Seventy‐seven percent of patients survived to undergo allogeneic hematopoietic cell transplantation. Patients experienced an acceptable spectrum of complications, including CMV and adenovirus viremia. Conclusion Alemtuzumab appears to be an effective salvage agent for refractory HLH, leading to improvement and survival to HCT in many patients. Prospective trials to define optimal dosing levels, schedules, and responses are needed. Pediatr Blood Cancer 2013; 60: 101–109.Keywords
Funding Information
- NIH (R01HL091769)
- Clinical Immunology Society
This publication has 21 references indexed in Scilit:
- Rapid and Sustained Remission of Systemic Juvenile Idiopathic Arthritis-Associated Macrophage Activation Syndrome Through Treatment With Anakinra and CorticosteroidsJCR: Journal of Clinical Rheumatology, 2011
- Success with infliximab in treating refractory hemophagocytic lymphohistiocytosisAmerican Journal of Hematology, 2005
- Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosisBritish Journal of Haematology, 2005
- A novel reduced-intensity stem cell transplant regimen for nonmalignant disordersBone Marrow Transplantation, 2004
- An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorderBlood, 2004
- Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantationBlood, 2002
- α‐CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosisMedical and Pediatric Oncology, 2002
- Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society.1999
- Characterization of the CAMPATH‐1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backboneEuropean Journal of Immunology, 1991
- The CAMPATH‐1 antigen (CDw52)Tissue Antigens, 1990